Biological diagnosis of inflammatory bowel disease: current ideas and future achievements.

Abstract

Article presents review of new biological methods for the diagnosis of IBD. The problem of late diagnosis of IBD remains relevant because of increased frequency of adverse consequences of the disease by increasing the length of the period when patients do not receive adequate treatment. Well-known today are biological markers of inflammatory bowel disease, which are determined by non-invasive methods and are often an alternative to colonoscopy. C-reactive protein (CRP) is recognized as one of the most important proteins in the acute inflammation phase. Changes in the content of fecal calprotectin (FCP) in patients with IBD due to the clinical activity of inflammatory bowel disease and are closely related to the extent of colon damage. New fecal biomarkers such as Defensin, Myeloperoxidase, Pyruvate kinase, Lipocalin and others are a sensitive tool for screening for inflammation of the intestine and an indicator of its severity. New fecal markers may help improve the diagnosis, evaluation, and clinical outcomes of treatment of patients with inflammatory bowel disease.